Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2026 07:30 ET | Source: HCW Biologics Inc.

HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies

HCW11-040 is a pembrolizumab-based fusion immunotherapeutic that activates immune cells and eliminates high-oxygen induced senescent cells BPD is a rare pediatric disease affecting underweight...